Literature DB >> 26726080

Evaluation of the Modified Medical Research Council Dyspnea Scale for Predicting Hospitalization and Exacerbation in Japanese Patients with Chronic Obstructive Pulmonary Disease.

Hiroki Natori1, Tomotaka Kawayama, Masashi Suetomo, Takashi Kinoshita, Masanobu Matsuoka, Kazuko Matsunaga, Masaki Okamoto, Tomoaki Hoshino.   

Abstract

OBJECTIVE: The modified Medical Research Council (mMRC) scale is recommended for conducting assessments of dyspnea and disability and functions as an indicator of exacerbation. The aim of this study was to investigate whether the mMRC scale can be used to predict hospitalization and exacerbation in Japanese patients with chronic obstructive pulmonary disease (COPD).
METHODS: In a previous 52-week prospective study, 123 patients with COPD were classified into five groups (grades 0 to 4) according to the mMRC scale and four groups (stages I to IV) according to the spirometric Global Initiative for Chronic Obstructive Lung Disease (GOLD) classification. The frequency and period until the first event of hospitalization and exacerbation were compared among the groups.
RESULTS: The population of patients who experienced hospitalization and exacerbation during the 52-week study period, with an mMRC scale grade of 4, 3, 2, 1 and 0 was 50.0 and 100, 55.6 and 88.9, 21.1 and 73.7, 2.6 and 48.7, and 4.0 and 22.0%, respectively. A multivariate analysis adjusted for the GOLD stage and age showed that the patients with an mMRC scale grade of ≥3 had higher frequencies of hospitalization and exacerbation than those with lower grades. Meanwhile, the patients with an mMRC scale grade of ≥2 showed a significantly earlier time until the first exacerbation, but not hospitalization, in comparison with those with grade 0.
CONCLUSION: The present results indicate that, among Japanese patients with COPD, those with an mMRC scale grade of ≥3 have a significantly poorer prognosis and that the mMRC scale can be used to predict hospitalization and exacerbation.

Entities:  

Mesh:

Year:  2016        PMID: 26726080     DOI: 10.2169/internalmedicine.55.4490

Source DB:  PubMed          Journal:  Intern Med        ISSN: 0918-2918            Impact factor:   1.271


  5 in total

1.  Chronic bronchitis is associated with severe exacerbation and prolonged recovery period in Chinese patients with COPD: a multicenter cross-sectional study.

Authors:  Ying Liang; Yahong Chen; Rui Wu; Ming Lu; Wanzhen Yao; Jian Kang; Baiqiang Cai; Xin Zhou; Zheng Liu; Ping Chen; Dejun Sun; Jingping Zheng; Guoyang Wang; Yulin Feng; Yongjian Xu
Journal:  J Thorac Dis       Date:  2017-12       Impact factor: 2.895

2.  Psycho-Physiological Associates of Dyspnea in Hospitalized Patients with Interstitial Lung Diseases: A Cross-Sectional Study.

Authors:  Yan Hua Zhou; Yim Wah Mak
Journal:  Int J Environ Res Public Health       Date:  2017-10-24       Impact factor: 3.390

3.  Characteristics of 2017 GOLD COPD group A: a multicenter cross-sectional CAP study in Japan.

Authors:  Keiji Oishi; Tsunahiko Hirano; Kazuki Hamada; Sho Uehara; Ryo Suetake; Yoshikazu Yamaji; Kosuke Ito; Maki Asami-Noyama; Nobutaka Edakuni; Kazuto Matsunaga
Journal:  Int J Chron Obstruct Pulmon Dis       Date:  2018-12-05

Review 4.  Understanding low COPD exacerbation rates in Japan: a review and comparison with other countries.

Authors:  Takeo Ishii; Masaharu Nishimura; Asako Akimoto; Mark H James; Paul Jones
Journal:  Int J Chron Obstruct Pulmon Dis       Date:  2018-10-26

5.  Clinical impacts of the classification by 2017 GOLD guideline comparing previous ones on outcomes of COPD in real-world cohorts.

Authors:  Jin Hwa Song; Chang-Hoon Lee; Soo-Jung Um; Yong Bum Park; Kwang Ha Yoo; Ki Suck Jung; Sang-Do Lee; Yon-Mok Oh; Ji Hyun Lee; Eun Kyung Kim; Deog Kyeom Kim
Journal:  Int J Chron Obstruct Pulmon Dis       Date:  2018-10-23
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.